To determine if tadalafil 5 mg daily compared to placebo when given for 12 weeks improves getting and maintaining an erection in men with erectile dysfunction and if there are improvements in the sexual quality of life of the man and his female study...
Date First Received: January 16, 2007
Last Updated: June 8, 2009
Verified by: Eli Lilly and Company, June 2009
Clinical Trial Phase: Phase 3 | Start Date: November 2006
Overall Status: Completed
Estimated Enrollment: 342
Brief Summary
Official Title: “Tadalafil 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction and Sexual Quality of Life”
Condition Keyword(s):
Intervention(s):
To determine if tadalafil 5 mg daily compared to placebo when given for 12 weeks improves getting and maintaining an erection in men with erectile dysfunction and if there are improvements in the sexual quality of life of the man and his female study partner
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Study Primary Completion Date: January 2008
Intervention(s) in this Clinical Trial
- Drug: tadalafil
- 5 mg tadalafil tablet taken by mouth once a day for 12 weeks
- Drug: Placebo
- placebo tablet taken by mouth once a day for 12 weeks
Arms, Groups and Cohorts in this Clinical Trial
- Placebo Comparator: 1
- Placebo
- Active Comparator: 2
- 5 mg tadalafil
Outcome Measures for this Clinical Trial
Primary Measures
- Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF)- Erectile Function Domain Score (Sum of IIEF Questions 1-5 and
15)
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
- Improvement in the Sexual Quality of Life in the Subject and His Study Partner as Measured by the Sexual Quality of Life (SQoL) Domain of the Sexual Life
Quality Questionnaire (SLQQ)
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
- Change From Baseline to Endpoint in the Percent of "Yes" Responses to Sexual Encounter Profile (SEP) Diary Questions 2 (SEP2) and 3 (SEP3).
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
Secondary Measures
- Change From Baseline to Week 12 Endpoint in the International Index of Erectile Function - Intercourse Satisfaction Domain - Subject Response
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
- Change From Baseline to 12 Week Endpoint in Overall Satisfaction Domain of the International Index of Erectile Function (IIEF-OS) - Subject Response
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
- Sexual Life Quality Questionnaire (SLQQ) Treatment Satisfaction Domain
- Time Frame: 12 weeks
Safety Issue?: No
- Time Frame: 12 weeks
- Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Sexual Encounter Profile (SEP) Questions 4 and 5 - Subject Response
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
- Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Question 3 - Partner Response
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
- Change From Baseline to 12 Week Endpoint in the Satisfaction Domain of the Female Sexual Function Index (FSFI) - Partner Response
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
- Percent of Subjects With "Yes" Responses to Global Assessment Questionnaire (GAQ) - Subject Response
- Time Frame: 12 weeks
Safety Issue?: No
- Time Frame: 12 weeks
- Percent of Partners With "Yes" Responses to Global Assessment Questionnaire (GAQ) - Partner Response
- Time Frame: 12 weeks
Safety Issue?: No
- Time Frame: 12 weeks
- Change From Baseline to 12 Week Endpoint in Percent of "Yes" Responses to Partner-Sexual Encounter Profile (SEP) Questions 1 and 2 - Partner
Response
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
- Change From Baseline to 12 Week Endpoint in the Self-Esteem and Relationship (SEAR) Questionnaire
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
- Change From Baseline to 12 Week Endpoint in the Self-Esteem and Relationship (SEAR) Questionnaire - Confidence Domain Subscales
- Time Frame: Baseline and 12 weeks
Safety Issue?: No
- Time Frame: Baseline and 12 weeks
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Male
- History of erectile dysfunction (ED) for at least 3 months duration
- Anticipate having the same female partner willing to participate throughout the study
- At least 18 years of age at Visit 1 and agree to make at least 4 sexual attempts during the early phase of the study
- Adequate partner sexual function as determined by a Female Sexual Function Index
- Willing to record responses to efficacy questionnaires, sexual quality of life questionnaires and other instruments used in the study
Exclusion Criteria:
- May not participate in the study if you have taken tadalafil previously.
- History of cardiac conditions including angina requiring treatment with nitrates, heart disease of coronary conditions including myocardial infarction, bypass surgery, angioplasty or stent placement for specified time before starting the study.
- Have sexual partner not willing to complete the scales.
- Use of nitrates.
Gender Eligibility for this Clinical Trial: Male
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Eli Lilly and Company
Overall Clinical Trial Officials and Contacts
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Study Director Eli Lilly and Company
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00422734
Study ID Number: 9501
ClinicalTrials.gov Identifier: NCT00422734
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.